News
Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...
MyChesCo on MSN12h
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia GravisHOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback